News | August 11, 2024
HealthCare Global Enterprises posts Q1 FY25 PAT higher at Rs. 12.1 Cr
Our centers are performing as expected or even better
Our centers are performing as expected or even better
The results are an outcome of the company's focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years
Both departments will be equipped with specialized professionals and state-of-the-art facilities ensuring the highest standards of care
To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
The inspection scope included 6 separate Biologics manufacturing units comprising 4 Drug Substance and 2 Drug Product manufacturing plants
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
This strategic move aims to make Cupid's high-quality products more accessible to consumers nationwide
Reported profit after tax declined 19% year-on-year to Rs 76 crores
Subscribe To Our Newsletter & Stay Updated
